NCT06611046 is a clinical trial of organ donor in MicroRNA Profile, sponsored by Mar Dalmau.

Who is sponsoring NCT06611046?

NCT06611046 is sponsored by Mar Dalmau.

What drugs are being tested in NCT06611046?

Interventions in NCT06611046: organ donor.

What condition does NCT06611046 study?

NCT06611046 studies MicroRNA Profile, Liver Transplant, Organ Donor.

Is NCT06611046 still recruiting?

NCT06611046 is currently completed. Last updated 24 September 2024.

Last reviewed 2024-09-24 · How we verify

NCT06611046

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MicroRNA Profile As a Biomarker of Liver Damage in Different Types of Liver Donors.

Completed Last updated 24 September 2024

What this trial tests

trial testing organ donor in MicroRNA Profile in 28 participants. Completed in 1 September 2024.

Timeline

2 October 2019

Primary endpoint
27 July 2021

1 September 2024

Quick facts

Lead sponsor	Mar Dalmau
Status	Completed
Study type	OBSERVATIONAL
Enrollment	28
Start date	2 October 2019
Primary completion	27 July 2021
Estimated completion	1 September 2024
Sites	1 location across Spain

Drugs / interventions tested

organ donor

Conditions studied

MicroRNA Profile — all drugs for MicroRNA Profile →
Liver Transplant — all drugs for Liver Transplant →
Organ Donor — all drugs for Organ Donor →

Sponsor

Mar Dalmau

Who can join

18 and older, any sex, with MicroRNA Profile or Liver Transplant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to analyze the expression of liver-derived miRNAs in different types of liver donors to gain in depth knowledge about distinctive physiologic features within donors and find potential biomarkers for graft quality assessment. The main questions it aims to answer are: Is there a distinctive miRNA profile between donors after brain-stem death and donors after circulatory death? Is heparinase I treatment necessary to overcome miRNA quantification interference in heparinized liver donor samples ? Researchers will compare miRNA expression in donors after brain-stem death and donors after circulatory death with I) a subgroup of donors with unusable grafts due to significant steatosis, 2) and with a subgroup of healthy controls undergoing elective cholecystectomy to set the reference miRNA profiles in extreme conditions.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Heparinase I treatment to overcome RNA quantification interference in heparinized liver donor samples: One size fits all?
Dalmau M, Charco R, Bilbao I, Dopazo C, et al · · 2025 · PMID 40354476 · DOI 10.1371/journal.pone.0322899

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06611046 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mar Dalmau
Last refreshed: 24 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06611046.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing